Tonix Pharmaceuticals Holding (TNXP) Retained Earnings (2010 - 2026)

Tonix Pharmaceuticals Holding has reported Retained Earnings for 17 years, with the latest figure at -$935.5 million in Q2 2026.

• On a quarterly basis, Retained Earnings fell 20.58% year-over-year to -$935.5 million in Q2 2026; TTM through Jun 2026 was -$935.5 million, a 20.58% decrease from a year earlier, with the FY2025 full-year figure at -$854.7 million, down 16.97% from the prior year.
• Retained Earnings was -$935.5 million for Q2 2026 at Tonix Pharmaceuticals Holding, down from -$894.9 million in the prior quarter.
• The five-year high for Retained Earnings was -$386.2 million in Q1 2022, with the low at -$935.5 million in Q2 2026.
• Average Retained Earnings over 5 years is -$650.3 million, with a median of -$655.0 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2025: Retained Earnings slumped 34.02% in 2022, then retreated 11.73% in 2025.
• Over 5 years, Retained Earnings stood at -$470.0 million in 2022, then decreased by 27.79% to -$600.7 million in 2023, then dropped by 21.65% to -$730.7 million in 2024, then dropped by 16.97% to -$854.7 million in 2025, then slipped by 9.45% to -$935.5 million in 2026.
• The last three Retained Earnings figures came in at -$935.5 million (Q2 2026), -$894.9 million (Q1 2026), and -$854.7 million (Q4 2025), per Business Quant data.